Stock screenerAll disclosures →
EDGAR →
PRME
Conviction 35HealthcareScan · Fri, Jun 26, 2026PRME$3.43+7.86%
ResistanceSupportVol 14Vol MA14 3.07M
Mar 27Apr 15May 4May 20Jun 9Jun 26
Price3.43
Change+7.86%
Gap-0.63%
Rel volume1.81×
Avg volume3.19M
Avg $ vol10.09M
SMA 203.12
SMA 503.27
SMA 2003.94
Price vs 50+4.96%
Price vs 200-12.93%
MA stackmixed
50/200 cross—
Supertrendup · 2.65
RSI (14)58
MACD hist0.05
MACD crossbull · 6d
Stoch %K / %D84 / 63
ADX (14)16
+DI / −DI27 / 17
RSI divergence—
MACD divergence—
ATR %+8.07%
ADR %8.82%
52w high6.67
52w low2.42
From 52w high-48.58%
Above 52w low+41.74%
New 52w highNo
SqueezeOff
Bollinger width30.83%
%B0.82
Donchian pos80.84%
Donchian high3.61
Donchian low2.67
AVWAP (52w high)3.94
vs AVWAP high-13.05%
AVWAP (52w low)4.03
vs AVWAP low-14.85%
OBV trendFlat
Chaikin MF (20)-0.08
Today vs 20d1.81×
Avg vol (14d)3.07M
Avg vol (20d)3.19M
Avg $ vol (20d)10.09M
Market cap—
RS 3m (vs SPY)-24.19%
RS 6m (vs SPY)-21.28%
RS line new highNo
Trend template2/8
Technical rank43.9
1 week+6.19%
1 month+3.94%
3 months-5.77%
6 months-7.05%
1 year+41.74%
YTD-2.83%
P/E-2.86
P/B7.49
P/S124.00
P/FCF-3.44
EPS-1.35
Div yield—
ROE-262.25%
ROA-68.25%
Debt/Eq—
Current3.80
EV/EBITDA-2.54
Gross margin—
Net margin—
Rev growth55.28%
EPS growth-2.69%
Price target7.80
Target upside145.28%
Analyst ratingBuy
Institutional51.19%
Ent. value510.26M
Revenue1.23M
Net income-49.12M
Gross profit—
Free cash flow-167.09M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out180.62M
Employees146
ListedThu, Oct 20, 2022
Free float—
Float %—
Short interest—
Days to cover—
Short volume—
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction35 / 100
Pattern quality—
Tech rank43.9 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance3.59
Support2.68
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in PRME
No recent disclosed trades by Congress in PRME. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in PRME · 8 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Foster-Cheek Kaye I Director · Stock Option (right to buy) · 2026-06-05 | Grant | 75K | $0 | 2026-06-05 | 2026-06-08 |
Kelly Michael Aaron Director · Stock Option (right to buy) · 2026-06-05 | Grant | 75K | $0 | 2026-06-05 | 2026-06-08 |
NELSEN ROBERT Director · Stock Option (right to buy) · 2026-06-05 | Grant | 75K | $0 | 2026-06-05 | 2026-06-08 |
Cahill Thomas Director · Stock Option (right to buy) · 2026-06-05 | Grant | 75K | $0 | 2026-06-05 | 2026-06-08 |
Schenkein David P Director · Stock Option (right to buy) · 2026-06-05 | Grant | 75K | $0 | 2026-06-05 | 2026-06-08 |
Chung Wendy Director · Stock Option (right to buy) · 2026-06-05 | Grant | 75K | $0 | 2026-06-05 | 2026-06-08 |
Marrazzo Jeffrey D Director · Stock Option (right to buy) · 2026-06-05 | Grant | 75K | $0 | 2026-06-05 | 2026-06-08 |
Makhni Svetlana Ni Chief Financial Officer · Stock Option (right to buy) · 2026-04-16 | Grant | 800K | $0 | 2026-04-16 | 2026-04-17 |
SEC filings
EDGAR filings in PRME · 1 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.